Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director · CEO | March 17, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,078,922 |
Reported balance
After 2026-03-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-17 · Sale · Disposed 118,969 · Balance 1,078,922 F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2: Includes 457,500 RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 93,158 |
Reported balance
Holding disclosure · report date 2026-03-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 93,158 F3: Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
F2: Includes 457,500 RSUs.
F3: Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2026 Filed Mar 19, 2026 22:35 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 118,969 | $6.42 | $764,137.89 |
DisclosureSEC source: 0001610717-26-000124 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,078,922 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · balance_after: Includes 457,500 RSUs. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:22 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 980,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001610717-26-000039 · form4.xml · derivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 980,000 Underlying: Common Stock · 980,000 shares Expires 2036-02-01 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:22 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 210,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000039 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,197,891 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: Includes 698,750 RSUs. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 21:05 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleClass A Common Stock | 101,793 | $4.54 | $461,906.10 |
DisclosureSEC source: 0001610717-25-000372 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 987,891 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 27, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $4.50 to $4.62, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Includes 488,750 restricted stock units. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 22:40 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantPerformance Stock Units (PSUs) · Derivative | 285,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000357 · form4.xml · derivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,000 Underlying: Common Stock · 285,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. F2 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. F2 · derivative.expiration_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 22:40 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 570,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001610717-25-000357 · form4.xml · derivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 570,000 Underlying: Common Stock · 570,000 shares Expires 2035-09-25 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| June 16, 2025 Filed Jun 17, 2025 20:09 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 55,511 | $2.69 | $149,263.53 |
DisclosureSEC source: 0001610717-25-000234 · form4.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,089,684 F3 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs. F2 · balance_after: Includes 488,750 restricted stock units. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:09 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionPerformance Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000234 · form4.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each PSU represented a contingent right to receive one (1) share of common stock upon vesting. F5 · derivative.exercise_date: Each PSU represented a contingent right to receive one (1) share of common stock upon vesting. F5 · derivative.expiration_date: Each PSU represented a contingent right to receive one (1) share of common stock upon vesting. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:09 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000234 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,145,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction represents the vesting of performance stock units ("PSUs") initially granted on February 2, 2023. F2 · balance_after: Includes 488,750 restricted stock units. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 20:34 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 37,656 | $0.60 | $22,555.94 |
DisclosureSEC source: 0001610717-25-000086 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 995,195 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · balance_after: Includes 488,750 RSUs. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 22:54 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 390,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001610717-25-000016 · form4.xml · derivative · entry 5 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2035-02-03 F6 · derivative.exercise_date: 1/24th of the shares subject to the option vest on each monthly anniversary measured from the Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 22:54 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 800,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001610717-25-000016 · form4.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2035-02-03 F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 4, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 22:54 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 195,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000016 · form4.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,032,851 F2 · shares: Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest annually on March 15 of each year, with the first 50% vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date. F3 · balance_after: Includes 572,500 RSUs. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 22:54 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 180,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000016 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 837,851 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 21:58 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionPerformance Stock Units (PSUs) · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000432 · form4.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone. F1 · kind: Represents vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022. F5 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone. F5 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 21:58 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 13,898 | $1.23 | $17,082.03 |
DisclosureSEC source: 0001610717-24-000432 · form4.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 657,851 F3 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein. F2 · balance_after: Includes 197,500 restricted stock units. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 21:58 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000432 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 671,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022. F2 · balance_after: Includes 197,500 restricted stock units. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 23:12 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 109,768 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001610717-24-000190 · form4.xml · derivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,768 shares Expires 2025-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested and exercisable. F4 · balance_after: The Reporting Person previously transferred 9,768 shares subject to this stock option to a family member. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 23:12 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 109,768 | $1.57 | $172,873.62 |
DisclosureSEC source: 0001610717-24-000190 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 634,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 197,500 restricted stock units. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 20:40 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 20,223 | $2.09 | $42,175.07 |
DisclosureSEC source: 0001610717-24-000178 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,481 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 197,500 restricted stock units. Read SEC document |
| January 18, 2024 Filed Jan 20, 2024 01:44 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantPerformance Stock Units (PSUs) · Derivative | 260,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000036 · form4.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires not disclosed F5 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. F5 · derivative.exercise_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. F5 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 18, 2024 Filed Jan 20, 2024 01:44 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 420,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001610717-24-000036 · form4.xml · derivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,000 Underlying: Common Stock · 420,000 shares Expires 2034-01-17 F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 18, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| January 18, 2024 Filed Jan 20, 2024 01:44 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000036 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,704 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2025, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: Includes 251,250 RSUs. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 21:16 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 13,551 | $1.38 | $18,709.87 |
DisclosureSEC source: 0001610717-23-000423 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 454,704 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs previously reported on December 19, 2023. F2 · balance_after: Includes 161,250 restricted stock units. Read SEC document |
| December 17, 2023 Filed Dec 20, 2023 00:57 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionPerformance Stock Units (PSUs) · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000411 · form4.xml · derivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents partial vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022. F1 · kind: Represents partial vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022. F4 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024. F4 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024. Read SEC document |
| December 17, 2023 Filed Dec 20, 2023 00:57 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000411 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents partial vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022. F2 · balance_after: Includes 161,250 restricted stock units. Read SEC document |
| September 22, 2023 Filed Sep 22, 2023 23:13 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 14,601 | $1.30 | $18,987.14 |
DisclosureSEC source: 0001610717-23-000297 · form4.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,755 F3 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs. F2 · balance_after: Includes 161,250 restricted stock units. Read SEC document |
| September 20, 2023 Filed Sep 22, 2023 23:13 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000297 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 445,356 F1 · kind: Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The second milestone vesting condition was determined to be satisfied upon which the remaining 50% of the PSUs vested. F2 · balance_after: Includes 161,250 restricted stock units. Read SEC document |
| May 19, 2023 Filed May 23, 2023 20:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,535 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001610717-23-000061 · form4.xml · derivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,536 Underlying: Common Stock · 16,535 shares Expires 2025-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| May 19, 2023 Filed May 23, 2023 20:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 16,535 | $1.57 | $26,040.97 |
DisclosureSEC source: 0001610717-23-000061 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 405,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 161,250 restricted stock units. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 22:43 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 7,121 | $1.88 | $13,391.04 |
DisclosureSEC source: 0001140361-23-012618 · form4.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388,821 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 161,250 restricted stock units. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:50 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantPerformance Stock Units (PSUs) · Derivative | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-001930 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires not disclosed F5 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. F5 · derivative.exercise_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. F5 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:50 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 315,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001567619-23-001930 · doc1.xml · derivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,000 Underlying: Common Stock · 315,000 shares Expires 2033-02-01 F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:50 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-001930 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,942 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: Includes 180,000 RSUs. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 21:01 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantPerformance Stock Units (PSUs) · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-015868 · doc1.xml · derivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024. F2 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024. F2 · derivative.expiration_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 21:01 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001567619-22-015868 · doc1.xml · derivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2032-08-09 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:10 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 14,911 | $1.42 | $21,206.42 |
DisclosureSEC source: 0001567619-22-014299 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,942 F3 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer. F2 · balance_after: Includes 75,000 restricted stock units. Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 20:10 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-014299 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,853 F1 · kind: Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested. F2 · balance_after: Includes 75,000 restricted stock units. Read SEC document |
| May 09, 2022 Filed May 11, 2022 20:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,189 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001567619-22-010091 · doc1.xml · derivative · entry 5 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,189 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 09, 2022 Filed May 11, 2022 20:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 66,742 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001567619-22-010091 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,742 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 09, 2022 Filed May 11, 2022 20:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 24,189 | $0.95 | $22,858.61 |
DisclosureSEC source: 0001567619-22-010091 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 75,000 restricted stock units. Read SEC document |
| May 09, 2022 Filed May 11, 2022 20:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 66,742 | $0.95 | $63,071.19 |
DisclosureSEC source: 0001567619-22-010091 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 75,000 restricted stock units. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 21:49 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001567619-22-002521 · doc1.xml · derivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2032-02-01 F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 21:49 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-002521 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,922 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on March 15 of each year, with the first 1/4th vesting on March 15, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 75,000 RSUs. Read SEC document |
| October 24, 2021 Filed Oct 26, 2021 20:30 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantPerformance Stock Units (PSUs) · Derivative | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-018720 · doc1.xml · derivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date. F2 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date. F2 · derivative.expiration_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date. Read SEC document |
| October 24, 2021 Filed Oct 26, 2021 20:30 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $5.34 | $0.00 |
DisclosureSEC source: 0001567619-21-018720 · doc1.xml · derivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-10-23 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from October 24, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 21:22 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 92,113 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001567619-21-015554 · doc1.xml · derivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 92,113 shares Expires 2021-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Exercise of September 2021 expiring stock options with cash. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 21:22 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 92,113 | $1.13 | $104,446.93 |
DisclosureSEC source: 0001567619-21-015554 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities held has been adjusted to reflect the transfer of 40 shares previously owned directly to Sean A. McCarthy 2018 Trust. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 19:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 100,000 | $7.04 | $704,470.00 |
DisclosureSEC source: 0001567619-21-012419 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 93,118 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades in prices ranging from $6.88 to $7.135, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 01:49 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001567619-21-012252 · doc1.xml · derivative · entry 5 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,742 Underlying: Common Stock · 10 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.